Sterile Fill-Finish CDMO Onboarding Checklist 2026

Onboarding a sterile injectable fill-finish Contract Development and Manufacturing Organisation (CDMO) involves eight structured steps: defining your manufacturing requirements, establishing selection criteria, conducting a formal technical audit, completing a feasibility assessment, compiling Chemistry, Manufacturing and Controls (CMC) documentation for European Medicines Agency (EMA) and Food and Drug Administration (FDA) submissions, executing clinical-to-commercial technology transfer, verifying Good Manufacturing Practice (GMP) readiness and building supply chain resilience.

This guide is written for pharmaceutical and biotechnology CMC leaders and clinical supply teams preparing to initiate, transition or strengthen a sterile fill-finish CDMO relationship in 2026. Each step is supported by documented evidence requirements and regulatory compliance checkpoints aligned to current EMA and FDA expectations.

Why Structured Onboarding Is Critical for Sterile Injectable Manufacturing

Sterile injectable fill-finish is one of the most technically demanding and heavily regulated disciplines in pharmaceutical manufacturing. Failures in aseptic process control, container closure integrity or environmental monitoring can result in batch rejections, regulatory observations, clinical supply disruptions and direct risk to patient safety.

A structured, fully documented onboarding process protects against these outcomes. It establishes clear technical expectations between sponsor and CDMO, aligns quality systems before the first GMP batch and generates the regulatory-grade evidence base required for EMA and FDA dossier submissions.

The checklist that follows reflects current regulatory expectations under revised EU GMP Annex 1 (2022) and FDA guidance on sterile drug manufacturing.

Step 1: Define Your Sterile Injectable Manufacturing Requirements

Before approaching any CDMO, document your technical and commercial requirements comprehensively. This specification becomes the baseline for every feasibility, contractual and regulatory conversation that follows.

Dosage Form and Container Format

Identify which primary container format your product requires:

• Liquid vials
• Lyophilised vials (freeze-dried)
• Prefilled syringes
• Ampoules (aseptic filling or terminal sterilisation)
• Intravenous bags

Container format determines which filling lines and lyophilisation equipment are required and whether the CDMO’s existing vial or syringe formats are compatible with your product specifications.

Molecule Type and Formulation Complexity

Establish whether your Active Pharmaceutical Ingredient (API) is a small molecule or a biological product. Biological products require specific controls around temperature sensitivity, shear stress during filling and container surface interactions. Confirm whether your formulation is a solution, suspension, emulsion or viscous liquid, as each presents distinct process challenges at filling scale.

Development Stage

Specify your immediate programme need: Clinical Trial Material (CTM) manufacturing for Phase I, Phase II or Phase III studies; pivotal batch manufacturing for regulatory submission; or commercial manufacturing for product launch and ongoing supply. If you anticipate progression from clinical to commercial scale, document this trajectory from the outset. Selecting a CDMO with capabilities at both scales avoids the cost and regulatory burden of a future site change.

Volume and Batch Size Requirements

Define your expected batch size range and projected annual volume. For early-phase programmes, confirm whether the CDMO can accommodate small batches without minimum volume restrictions. For commercial programmes, confirm maximum annual capacity across your required container formats and provide a five-year demand forecast where available, to allow the CDMO to assess capacity reservation requirements.

Target Regulatory Markets

List all markets where your product will be registered. Each carries distinct GMP compliance requirements:

• European Union: EU GMP, including revised Annex 1 (Manufacture of Sterile Medicinal Products, 2022)
• United States: FDA 21 CFR Parts 210 and 211
• Switzerland: Swissmedic
• Japan: Pharmaceuticals and Medical Devices Agency (PMDA)

A CDMO holding multiple regulatory certifications enables supply to multiple markets from a single manufacturing site, reducing complexity and cost.

Special Handling Requirements

Identify any controlled substance requirements, high-potency compound handling needs or cold chain and temperature-controlled storage and distribution requirements before beginning CDMO selection. These requirements significantly affect site eligibility and must be confirmed early in the process.

Step 2: Establish CDMO Selection Criteria

With requirements defined, develop a weighted evaluation scorecard to assess candidate CDMOs consistently across the following domains.

Technical Capability and Equipment

Confirm that the CDMO’s equipment portfolio matches your product’s requirements. For sterile injectable fill-finish, relevant technologies include:

• Restricted Access Barrier Systems (RABS) or isolator technology for aseptic filling
• Lyophilisation (freeze-drying) capacity appropriate to your batch size
• Clean-in-Place (CIP) and Sterilise-in-Place (SIP) systems
• Single-use components to reduce cross-contamination risk and cleaning validation burden
• Validated visual inspection and container closure integrity testing systems

Regulatory Certification Portfolio

A CDMO’s certification portfolio directly determines which markets your product can be supplied into without additional site qualification. Prioritise CDMOs holding EU GMP certification alongside FDA registration. Certifications for additional markets, such as Swissmedic for Switzerland and PMDA for Japan, expand commercial reach without requiring secondary manufacturing arrangements.

Clinical and Commercial Track Record

Request the following evidence from any candidate CDMO:

• The number of clinical batches manufactured annually across sterile dosage forms
• The number of successful commercial product launches supported
• The number and outcome of regulatory inspections within the previous three years
• The number of client audits accommodated per year, as an indicator of operational transparency

Batch Size Flexibility

For early-phase programmes, the absence of minimum batch size requirements reduces cost and eliminates unnecessary Active Pharmaceutical Ingredient consumption. For commercial programmes, confirm the CDMO’s maximum annual output and current capacity utilisation across the relevant dosage forms.

Intellectual Property Protection

Evaluate the regulatory and legal jurisdiction in which the CDMO operates. Some jurisdictions offer more robust intellectual property protections, a consideration of particular relevance for novel biological entities and first-in-class programmes.

Project Management Structure

Confirm whether the CDMO assigns a dedicated project manager or single point of contact per programme. Structured, documented communication between sponsor and CDMO is a direct mitigant against timeline and quality risks throughout the manufacturing lifecycle.

Step 3: Conduct a Formal Technical CDMO Audit

A formal quality audit of the CDMO’s facility and quality systems is a prerequisite to commercial onboarding. Most established CDMOs accommodate approximately ten to fifteen client audits per year; plan your audit schedule early to avoid programme delays.

Pre-Audit Documentation Review

Prior to the on-site visit, request and review:

• Current EU GMP and FDA compliance certificates
• Most recent regulatory inspection reports and the CDMO’s written responses to any observations
• Site Master File and Quality Management System (QMS) documentation
• Standard Operating Procedures (SOPs) for aseptic processing, environmental monitoring and batch record management

On-Site Facility Assessment

During the audit, assess:

• Cleanroom classification against EU GMP Annex 1 requirements (Grade A, B, C and D)
• Environmental monitoring programme design and trending data
• Equipment qualification status across filling lines and lyophilisers
• Maintenance records and calibration schedules for critical equipment
• Waste management and contamination control procedures
• Cold chain storage infrastructure and documented temperature excursion management procedures

Quality Systems Assessment

Evaluate:

• Deviation and out-of-specification investigation procedures and closure timelines
• Change control processes, particularly for equipment and process changes affecting registered products
• Corrective and Preventive Action (CAPA) system and the effectiveness of CAPA closure
• Annual Product Quality Review process and quality metrics reporting framework

Audit Outcome and Follow-Up

Document all findings, classify them by risk level and request written CAPA commitments from the CDMO for any observations before executing a commercial agreement.

Step 4: Complete the Feasibility and Onboarding Assessment

Following a satisfactory audit outcome, initiate a formal feasibility study. Established CDMOs typically define feasibility across three dimensions.

Technical feasibility confirms that the CDMO’s equipment, processes and cleanroom environments are compatible with your Active Pharmaceutical Ingredient, formulation and container format. It identifies any process development activities required before GMP manufacturing can begin.

Regulatory feasibility confirms that existing GMP certifications cover all target markets and identifies any site-specific regulatory constraints relevant to your product type or controlled substance requirements.

Budgetary and timeline feasibility establishes cost structures, batch pricing, milestone payment schedules and turnaround commitments from order placement to batch release and quality certification.

Once feasibility is confirmed, execute a Quality Agreement defining respective responsibilities for batch release, deviation management and regulatory filing. Alongside this, negotiate a Manufacturing Services Agreement or Master Service Agreement covering intellectual property, confidentiality and liability provisions.

Step 5: Compile CMC Documentation for EMA and FDA Submissions

The sterile fill-finish CDMO must be documented within your regulatory dossier. In the Common Technical Document format, Module 3 (Quality) is the primary CMC evidence package reviewed by both the EMA and FDA. The table below summarises the key documents required for a sterile injectable manufacturing site.

CMC Document	Description
Batch manufacturing record	Completed GMP batch record demonstrating process consistency across all critical process parameters
Process description	Detailed description of formulation, filling and lyophilisation processes with defined in-process controls
Cleaning validation summary	Evidence demonstrating equipment cleaning removes product residues to validated acceptance limits
Container closure integrity testing data	Data demonstrating primary packaging maintains sterility across the approved product shelf life
Analytical methods and validation reports	Validated methods for identity, assay, purity, particulate matter and sterility testing
Stability data	International Council for Harmonisation (ICH)-compliant stability data from applicable climate zones
Environmental monitoring data	Trend data from the aseptic manufacturing environment, including particulate and microbial monitoring
Aseptic Process Simulation records	Media fill data demonstrating consistent aseptic process control at the proposed filling scale

EU-Specific Requirement: Contamination Control Strategy

Under revised EU GMP Annex 1 (2022), CDMOs are required to maintain a documented Contamination Control Strategy (CCS). Verify that your chosen CDMO has implemented a current CCS and that its scope covers your specific product type and aseptic process design.

FDA-Specific Requirements

For products intended for the United States market, confirm that the CDMO is registered with the FDA and that its manufacturing facility is listed in your approved Biologics Licence Application (BLA) or New Drug Application (NDA). Process validation data must comply with the FDA’s 2011 Process Validation Guidance and demonstrate consistent process performance across the proposed commercial batch size.

Step 6: Execute Clinical-to-Commercial Technology Transfer

Technology transfer from clinical to commercial scale is a formally documented and regulated process requiring dedicated resources on both the sponsor and CDMO sides.

Technology Transfer Plan

Prepare a written Technology Transfer Plan that specifies:

• The scope of the transfer, covering manufacturing process, analytical methods and product specifications
• Roles and responsibilities for each party at every milestone
• A milestone-based timeline with defined acceptance criteria at each stage

Process Scale-Up Considerations

When transferring to commercial scale, evaluate the impact of scale on mixing dynamics, heat transfer, filtration surface area and filling line parameters. Conduct hold time studies at commercial scale and qualify the lyophilisation cycle at the receiving facility’s lyophiliser dimensions where applicable.

Analytical Method Transfer

All release and stability analytical methods must be formally transferred to the CDMO’s Quality Control laboratory. Method transfer protocols and reports must demonstrate analytical equivalence between the originating and receiving sites, generating documented data for regulatory submission.

Regulatory Filing for Scale and Site Changes

Depending on the nature of the change, a Prior Approval Supplement (FDA) or a Type II variation (EMA) may be required before commercial batches can be released to market. Engage your regulatory affairs team at the earliest stage of technology transfer planning to define the regulatory strategy and avoid filing delays.

Process Validation

Commercial manufacturing requires documented evidence of process consistency. This is typically achieved through three consecutive validation batches or a continued process verification approach, subject to regulatory agreement. All validation data must be captured in a Process Validation Report filed within your product dossier.

Step 7: Verify GMP, EMA and FDA Readiness

Prior to the first commercial batch, conduct a structured readiness review against the following compliance checkpoints.

EU GMP Annex 1 Compliance (2022)

• Contamination Control Strategy documented and approved by site quality management
• RABS or isolator technology in use for all aseptic filling operations
• Environmental monitoring programme validated and trending within alert and action limits
• Aseptic Process Simulation completed within the required frequency with media fill units within acceptance criteria
• Container closure integrity testing approach justified and validated for the specific container and closure system

FDA Readiness

• CDMO facility listed in the approved NDA or BLA
• Process validation data completed and on file for the commercial batch size
• Data integrity compliance verified against FDA 21 CFR Part 11 requirements for electronic records and signatures

Qualified Person Certification

For EU batch release, confirm the CDMO employs a Qualified Person (QP) authorised to certify batches under EU GMP Chapter 1 and Directive 2001/83/EC. Confirm that QP certification scope covers your specific product category, whether small molecule or biological entity.

Step 8: Build Supply Chain Resilience

Sterile injectable fill-finish supply chains carry meaningful disruption risk, including raw material shortages, unplanned regulatory holds and site-specific capacity constraints. Resilience planning should begin during CDMO onboarding, not in response to an event.

• Dual-source strategy: Where commercially viable, qualify a secondary CDMO or second manufacturing site capable of producing your product format, to provide continuity in the event of primary site disruption.
• Safety stock levels: Agree minimum safety stock thresholds and establish re-order triggers aligned to your demand forecast and batch release timelines.
• Raw material supply agreements: For critical components including primary containers, rubber stoppers and the Active Pharmaceutical Ingredient, confirm that the CDMO holds pre-qualified alternative supplier lists or establish direct supply agreements to reduce single-source dependency.
• Serialisation compliance: Confirm the CDMO is compliant with EU Falsified Medicines Directive (FMD) serialisation requirements and can support track-and-trace obligations across all target markets.
• Business continuity planning: Request a copy of the CDMO’s business continuity and disaster recovery plan and evaluate its coverage of scenarios relevant to your product programme and contractual supply commitments.

How Adragos Pharma Supports Sterile Fill-Finish Programmes

Adragos Pharma operates a dedicated sterile manufacturing cluster comprising facilities in Jura (Switzerland), Maisons-Alfort (France) and Livron (France), with visual inspection and packaging capabilities at its facility in Kawagoe (Japan). The cluster is structured to support programmes from Clinical Trial Material manufacturing through to high-volume commercial supply, managed within a single partner network.

Jura, Switzerland: Clinical and Commercial Fill-Finish for Vials

The Jura facility holds over 25 years of specialisation in aseptic fill-finish for liquid and lyophilised vials, serving both small molecule and biological products. Certified by the EMA, FDA and Swissmedic, the site produces approximately 200 clinical batches per year and has supported five successful commercial product launches. There is no minimum batch size requirement, with capacity for up to 74,000 vials per batch in formats from 2R to 30R.

The facility offers a three-month turnaround from order placement to batch release, including controlled substance handling. Lyophilisers of 3m² and 9m² capacity are available alongside RABS-protected aseptic filling and a single-use strategy that minimises cross-contamination risk and reduces cleaning validation burden. Stability studies are conducted under ICH long-term conditions with full analytical testing at intermediate and final stability points.

Maisons-Alfort, France: Large-Scale Commercial Sterile Manufacturing

The Maisons-Alfort facility has over 77 years of experience in sterile drug manufacturing and specialises in prefilled syringes (0.5mL and 1mL formats) as well as liquid and lyophilised vials (formats: 6R, 10R, 7mL, 10mL, 15mL and 22mL). High-speed filling lines deliver up to 540 units per minute, supported by 100% automated inspection at up to 600 units per minute.

The site holds EU GMP certification and is certified by 12 international health authorities. It operates under RABS and CIP/SIP aseptic controls and provides fully compliant Aseptic Process Simulation (APS) services, making it well-positioned for programmes requiring FDA readiness alongside EU batch release.

Livron, France: Sterile Ampoules and Suppositories

The Livron facility specialises in sterile ampoule manufacturing in formats from 1mL to 10mL, using both aseptic filling and terminal sterilisation by heat, alongside suppository and ovule manufacturing. With an annual capacity of 120 million units, the site operates four production lines, two of which incorporate RABS technology. It holds EU GMP certification alongside manufacturing authorisations from the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French Agency for Food, Environmental and Occupational Health Safety (ANSES).

Clinical-to-Commercial Continuity Within a Single Partner Network

The Adragos sterile cluster supports end-to-end programme progression, from technical feasibility through GMP-compliant clinical batch production to high-volume commercial supply, managed by a dedicated sterile cluster team. This structure enables seamless technology transfer between clinical and commercial scale facilities within a single partner framework, without the regulatory and operational complexity associated with changing CDMO partners mid-programme.

FAQs About Sterile Fill-Finish CDMO Onboarding